Research Molecules

PNB Vesper is focused on developing cost-effective drugs for unmet medical needs. We have synthesized hundreds of molecules and systematically characterized them to select the lead molecules. The lead molecules have the potential to treat a variety of diseases including Covid 19, Inflammatory pain, Different kinds of Cancer, Inflammatory bowel disease (IBD), Neurological diseases such as Anxiety and Depression, Metabolic disorders, and others.

Molecules	Molecular target	Therapeutic indication	Stage of development & comments
PNB-001	Dual mechanism (CCK-A receptor agonist and CCK-B receptor antagonist)	Ulcerative Colitis and Crohn’s Disease Diabetes (T2D) COVID 19 Opioid & Cocaine addiction disorder	Clinical Phase-2 is completed, observed significant clinical activity compare to SOC and approved drugs. We are preparing phase-3 clinical protocol for CDSCO approval. Preclinical efficacy studies ongoing with, NIDA, US govt. institute. Initiated phase-2 clinical trial in India Clinical Phase 3 Ongoing (India), we have seen very exciting data in phase-2 study for moderate to high risk patients, helps in protecting lung inflammation and ARDS	View
PNB-028	Selective CCK-A antagonist	Colon and Pancreatic Cancer	Based on very good pre-clinical efficacy and safety data, Clinical Phase 1/2 trial is on-going in India	View
PNB-081	CCK-A antagonist	Opioid Disorder Management (Association with NIH- USA) Pancreatitis	Completed preclinical studies Completed preclinical studies	View
PNB-101	CCK3b or CCK C gastrin isoform-selective irreversible antagonist	Gastric Cancer and Lung Cancer.	Completed preclinical studies	View
PNB-091	Mixed CCK antagonist	Cocaine addiction Disorder (Association with NIH – USA)	Preclinical studies Partly completed Ready to start IND Regulatory studies	View
PNB-291	Pan-CCK blocker	Brain cancer CCK mediated cancers like Lung cancer, Liver cancer etc.	Preclinical studies completed Ready to start IND Regulatory studies	View